Viewing Study NCT06591845



Ignite Creation Date: 2024-10-26 @ 3:40 PM
Last Modification Date: 2024-10-26 @ 3:40 PM
Study NCT ID: NCT06591845
Status: NOT_YET_RECRUITING
Last Update Posted: None
First Post: 2024-09-04

Brief Title: Thorough QTQTc TQT Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects
Sponsor: None
Organization: None

Study Overview

Official Title: A Single-Center Randomized Partially Double-Blind Placebo- and Active-Controlled Four-period Crossover Thorough QTQTc TQT Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a single-center randomized partially double-blind placebo and active-controlled 4-period crossover design thorough QTQTc TQT clinical study to evaluate the effects of ziresovir on cardiac repolarization in healthy subjects
Detailed Description: This clinical study is a single-center randomized partially double-blind placebo- and active-controlled four-period crossover design with healthy subjects comprising the enrolled population Ziresovir and placebo will be administered in a double-blind manner while moxifloxacin hydrochloride tablets will be administered in as open-label

Thirty-two subjects meeting all inclusion criteria and none of the exclusion criteria will be randomized into 1 of 12 dosing sequences each consisting of 4 periods with an 8-day washout period in-between

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None